Optimizing CMV therapy: Population pharmacokinetics and Monte Carlo simulations for letermovir and maribavir dosage. (PubMed, PLoS One) - Apr 28, 2025 - "Our findings suggest a strong rationale to reconsider and potentially modify the approved dosing guidelines for letermovir and maribavir in CMV treatment. Adjusting dosing regimens, including the use of loading doses and increased doses after missed doses, could enhance treatment outcomes by ensuring higher probabilities of achieving therapeutic targets and better managing missed doses."
Journal • PK/PD data • Cytomegalovirus Infection • Infectious Disease
|
|
Gilles Peytavin; Hamza Sayadi; Jean-Baptiste Woillard; Pierre Marquet; Sophie Alain; Yeleen Fromage
|